Browse
related articles
Most recently Mr. Toxvaerd was CEO of Neutrahealth Plc, an AIM listed acquisition vehicle focused on the alternative healthcare industry. He spent over four years spearheading its growth through acquisition, and worked closely with members of it's distinguished Board of Directors including Sir GK Noon.
During his tenure as CEO he also negotiated the strategic investment by Elder Pharma, a Mumbai based pharmaceuticals group, in Neutrahealth.
Zulfi Hydari, HBG Group Managing Director, commented:
"We are delighted to welcome Michael to HBG's senior management team. His extensive experience of running an AIM listed company is already proving to be invaluable as we engage with the management teams of various target companies. I am confident that his first-hand experience of issues that senior management of AIM companies face will be indispensable in reaching equitable deals."
Mr. Toxvaerd will spearhead the investment activities of HBG in London whilst working closely with the Private Equity and Principal Investment teams in the Gulf to develop strategic partnerships between HBG and London based financial institutions.
Mr. Toxvaerd said, "I am pleased to be joining a firm which combines financial strength with an entrepreneurial culture that promotes ownership by senior management. The opportunity is significant, we have alignment and there is no time to lose."
The London office will be fully integrated with HBG's offices in Dubai and Jeddah.
Digg
Facebook
LinkedIn
Twitter
Rana Mesbah
It looks like you are using a Mac - check out our 
Web Feeds